Bioactive Factor Combination for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies are costly, technically complex, and raise ethical concerns, while extracts from mammalian sources like serum, placenta, and colostrum, which contain regenerative factors, often lose important components during processing, lacking a comprehensive substitute for stem cell therapy.
Innovation Solution
A combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins, and chemotactic factors is extracted from serum, placenta, or colostrum, providing a multifunctional composition for tissue repair and regeneration, mimicking the effects of stem cell therapies without the ethical and cost issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell therapy is used to treat tissue repair and regeneration, then therapeutic effectiveness is improved, but cost and technical complexity increase significantly
Solution Approach 1:
The patent extracts and isolates specific bioactive factors (growth factors, cytokines, chemotactic factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins, and antibacterial/antiviral factors) from the complex stem cell system. This extraction allows the therapeutic benefits to be achieved through isolated active components rather than requiring complete stem cell therapy infrastructure, thereby reducing technical complexity while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent creates a simplified copy or model of stem cell therapy by using recombinant versions of the bioactive factors normally secreted by stem cells. These recombinant factors replicate the therapeutic functions of stem cells (promoting tissue repair, regeneration, and immune modulation) without requiring actual stem cell cultivation and injection procedures, thus reducing technical complexity and ethical concerns while preserving therapeutic effectiveness.
2Reliability
If stem cell therapy is used to treat tissue repair and regeneration, then therapeutic effectiveness is improved, but cost increases significantly
Solution Approach 1:
The patent employs recombinant bioactive factors that can be produced through standardized fermentation and purification processes, making them significantly cheaper than live stem cell products. These recombinant factors are stable, shelf-ready molecules that eliminate the need for expensive stem cell banking, cultivation facilities, and specialized administration infrastructure, thereby dramatically reducing treatment costs while maintaining therapeutic effectiveness.
3Ease of manufacture
If extracts from mammalian sources are used to provide regenerative factors, then availability and cost are improved, but important components are lost during processing
Solution Approach 1:
The patent utilizes recombinant DNA technology to produce bioactive factors in controlled expression systems with optimized parameters for yield and purity. By changing the production approach from traditional mammalian extraction to recombinant expression, the process achieves both high availability (through scalable fermentation) and complete component recovery (by selectively producing only the desired factors without processing losses).
Solution Approach 2:
The patent replaces mechanical extraction and purification processes (which cause component loss) with biological production systems. Recombinant cells are genetically engineered to directly synthesize and secrete the desired bioactive factors, eliminating the need for harsh extraction solvents, filtration steps, and concentration processes that typically result in loss of active components. This substitution of mechanical extraction with biological synthesis ensures complete recovery of all desired factors.
Data Source
AI summary
The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies.